Kim Huard joined Genentech in 2018 where she leads drug discovery programs. In 2008, she graduated from the Université de Montréal with a Ph.D. in organic chemistry where she developed a rhodium-catalysed carbon-hydrogen bond nitrene insertion methodology. Following her graduate studies, Kim contributed to the total synthesis of the structurally complex natural product daphnipaxinin as a FQRNT postdoctoral fellow at the University of California, Irvine. Kim joined Pfizer in 2010 as a medicinal chemist in the cardiovascular and metabolic disease research unit. Since 2012, she has been leading chemistry teams on various drug discovery programs which led to the discovery of three clinical candidates. Her work involves modulation of different types of biological targets with small molecules as well as targeting specific compound disposition such as liver selective or brain penetrant agents.